Benzinga | Nov 9, 2021 04:37PM EST

Jazz Pharmaceuticals Q3 EPS $4.20 Beats $3.31 Estimate, Sales $838.12M Beat $832.52M Estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $4.20 per share which beat the analyst consensus estimate of $3.31 by 26.89 percent. This is a 2.55 percent decrease over earnings of $4.31 per share from the same period last year. The company reported quarterly sales of $838.12 million which beat the analyst consensus estimate of $832.52 million by 0.67 percent. This is a 39.48 percent increase over sales of $600.89 million the same period last year.